● LIVEResearch grant for the advancement of our phage therapy/GMP-certified drug production in preparation/WHO classifies AMR as a global health threat/Research and development in bacteriophage biology/● LIVEResearch grant for the advancement of our phage therapy/GMP-certified drug production in preparation/WHO classifies AMR as a global health threat/Research and development in bacteriophage biology/

    The Delta G Avaris Approach: Personalized Phage Therapy for Broad Application

    Delta G Avaris aims to be a full-service provider for personalized phage therapy, combining pathogen analysis, a comprehensive phage bank, and GMP-certified production.

    01Our Solution

    Phage Therapy: An Approach in Infectious Disease Medicine

    Phage therapy is based on a principle discovered over 100 years ago and continues to evolve into a promising, highly targeted approach to combating bacterial infections. Our medical team has extensive experience in the use of phage therapy for patients with a wide variety of difficult-to-treat infections at Hannover Medical School (MHH), where promising results have been achieved. At Delta G Avaris, we aim to build on this expertise and advance it further while driving next-generation phage therapy technologies. We place particular emphasis on matching each phage specifically to the respective bacterial pathogen, enabling highly precise action while preserving the surrounding microbiome.

    Side-effect-free alternative
    to antibiotics
    100% tailored
    to the pathogen
    Highly effective, even in
    severe and chronic cases
    02The Science

    How Does Phage Therapy Work?

    Phage therapy uses special viruses called bacteriophages that infect and destroy specific bacteria.

    Unlike antibiotics, phages act only against the targeted pathogen, preserving the body's healthy microbiota. The WHO recognizes phages as a promising tool in the fight against antibiotic resistance; particularly against the so-called ESKAPE pathogens

    What Are ESKAPE Pathogens?

    ESKAPE pathogens represent six particularly dangerous bacterial species: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.

    They are named for their ability to "escape" standard antibiotic treatments and are responsible for serious hospital-acquired infections. The WHO classifies them among the world's most critical health threats.

    Delta G Avaris focuses initially on these pathogens, with a scalable approach adaptable to any bacterial target.

    03ESKAPE Pathogens

    No escape for ESKAPE. We have these pathogens in our sights!

    E.
    Enterococcus faecium
    Urinary tract infections, endocarditis, sepsis
    S.
    Staphylococcus aureus
    Skin and soft tissue infections, pneumonia, osteomyelitis, sepsis
    K.
    Klebsiella pneumoniae
    Pneumonia, urinary tract infections, sepsis
    A.
    Acinetobacter baumannii
    Pneumonia, wound/catheter infections, sepsis
    P.
    Pseudomonas aeruginosa
    Pneumonia, urinary tract infections, wound infections, sepsis
    E.
    Enterobacter spp.
    Pneumonia, urinary tract infections, sepsis

    The targeted selection of a single, highly specific phage based on a phagogram combines maximum efficacy with minimal side effects — making it the most precise approach in modern phage therapy.

    Three Approaches to Phage Therapy

    There are different strategies for using bacteriophages therapeutically. The degree of individualization significantly determines efficacy.

    Ready-Made Cocktails

    Pre-formulated phage mixtures

    Pre-made phage preparations with a fixed composition designed to target a broad range of pathogens.

    Cocktails with 3–4 Phages

    Tailored mixture

    A mixture of several phages tailored to the specific pathogen, with higher effectiveness than ready-made cocktails.

    Individualized Single Phages

    Our Approach
    Precisely matched to the pathogen

    Based on a phagogram, the single phage that combats the individual pathogen with maximum precision is identified.

    05Our Process
    The Analysis: Phagogram

    The Analysis: Phagogram

    In the case of an infection, the pathogen is first isolated and cultured. Potential candidates from our phage bank are then tested for their effectiveness in a process known as Phage Susceptibility Testing (PST). Based on this phagogram, we can determine with certainty which phage is best suited for the active substance.

    Our Phage Discovery Collection

    Our Phage Discovery Collection

    We are building a dynamic phage discovery collection designed to support the development of future precision therapies. This evolving library consists of phenotypically and genetically characterized bacteriophages and host bacteria, forming an important foundation for our long-term research ambitions. As the collection grows, we are advancing sophisticated analytical capabilities—including AI-supported methods—to explore how phage–pathogen matching could be optimized in future therapeutic applications.

    06Manufacturing

    GMP-Certified Manufacturing

    01

    Amplification

    Cultivation of bacteriophages on the relevant bacterial strain.

    02

    Purification

    Production of high-purity preparations suitable for oral, topical, inhalative, or intravenous use.

    03

    Quality Control

    Continuous testing and certification according to the European Pharmacopoeia.

    04

    Formulation

    Preparation for application in multiple forms as required.

    07Detailed Scientific Information

    Detailed Scientific Information

    Further study data and professional documentation are exclusively available to healthcare professionals.

    We use cookies to provide you with the best possible experience on our website. Learn more